PRESS RELEASE published on 02/17/2024 at 01:50, 2 years 3 months ago BioNxt Solutions Finalizes Agreement BioNxt Solutions Inc. finalizes Settlement Agreement with a creditor to settle $282,415 debt through issuance of common shares and a cash payment. Debt to be settled in three instalments of shares based on market price Common Shares Debt Settlement BioNxt Solutions Inc. Settlement Agreement Creditor
PRESS RELEASE published on 01/30/2024 at 05:48, 2 years 3 months ago BIONXT SOLUTIONS ANNOUNCES CLOSING OF FINAL TRANCHE OF NON-BROKERED PRIVATE PLACEMENT BioNxt Solutions Inc. closes final tranche of non-brokered private placement, raising gross proceeds of $288,000 to fund drug development and working capital purposes Private Placement Working Capital Investment Drug Development BioNxt Solutions Inc.
PRESS RELEASE published on 12/22/2023 at 09:05, 2 years 5 months ago BioNxt Solutions Announces Completion of Cladribine ODF Toxicity Study and Financing
PRESS RELEASE published on 12/22/2023 at 01:50, 2 years 5 months ago BioNxt Solutions Announces Completion of Cladribine ODF Toxicity Study and Financing
PRESS RELEASE published on 12/12/2023 at 09:05, 2 years 5 months ago BioNxt Receives Delivery of Premium Commercial Coating and Cutting Equipment for Commercial Manufacturing of Drug Delivery Products
PRESS RELEASE published on 12/09/2023 at 04:30, 2 years 5 months ago BioNxt Solutions Announces Completion of Debenture and Interest Settlement and Issuance of Finder’s Warrants
PRESS RELEASE published on 11/25/2023 at 01:44, 2 years 6 months ago Bionxt Solutions Announces Convertible Debenture and Interest Settlement
PRESS RELEASE published on 11/20/2023 at 09:05, 2 years 6 months ago BioNxt Accelerates Cladribine ODF Clinical and Commercialization Strategy for Multiple Sclerosis Treament
PRESS RELEASE published on 11/15/2023 at 09:05, 2 years 6 months ago BioNxt Reports on New Cladrabine ODF Product Development and Commercialization Program
PRESS RELEASE published on 11/13/2023 at 09:05, 2 years 6 months ago BioNxt Signs Definitive Agreement For 100% Acquisition of IP And Co-Development of Cladribine ODF Drug Reformulation for The Treatment of Multiple Sclerosis
Published on 05/25/2026 at 13:30, 6 hours 35 minutes ago ZTEST Electronics Inc. Announces Fiscal 2026 Q3 Results with 13.9% Year Over Year Revenue Growth
Published on 05/25/2026 at 13:30, 6 hours 35 minutes ago ESgold Corp. Engages ICP Securities for Automated Market Making Services
Published on 05/23/2026 at 03:15, 2 days 16 hours ago UraniumX Approved for Trading on the OTCQB Venture Market and Announces Board Change
Published on 05/23/2026 at 03:00, 2 days 17 hours ago Battery X Metals Reports Up to ~84 km Estimated Driving Range Increase Across Multiple BYD Electric Vehicles Following Next-Generation Patent-Pending Lithium-Ion Battery Rebalancing Trials, Demonstrating Performance Improvement Across the World’s Larges
Published on 05/25/2026 at 18:45, 1 hour 20 minutes ago 'Made in Binzhou' Heads to Tianzhou-10 Cargo Spacecraft——Binzhou Sci-Tech Power Embarks on a Hardcore Space Mission
Published on 05/25/2026 at 18:00, 2 hours 5 minutes ago Huawei Hosts 3rd Global C&I Visionaries Summit, Shaping a Greener Future Across Diverse Industries
Published on 05/25/2026 at 17:00, 3 hours 5 minutes ago TCMA x Chulalongkorn University Join Forces with Canadian Partners to Advance Strategic Collaboration for a Low-Carbon Industry toward Net Zero 2050
Published on 05/25/2026 at 16:31, 3 hours 33 minutes ago Form 8.3 - The Vanguard Group, Inc.: Tate & Lyle PLC
Published on 05/25/2026 at 16:30, 3 hours 35 minutes ago Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group PLC
Published on 05/22/2026 at 18:05, 3 days 2 hours ago Disclosure of transactions in own shares from May 18 to May 22, 2026
Published on 05/22/2026 at 12:52, 3 days 7 hours ago Release from the Board of Directors - Shareholders’ Meeting of May 22, 2026
Published on 05/22/2026 at 08:30, 3 days 11 hours ago Eiffage is building four solar power plants for the NOOR Atlas programme in Morocco
